The US Supreme Court in a landmark decision held that a DNA molecule is potentially eligible for patenting in the US if its sequence does not occur in nature, but is not patent-eligible if its sequence is identical to a naturally occurring DNA sequence.
James Monroe and Lawrence Ilag of Finnegan, Henderson, Farabow, Garrett & Dunner LLP analyse the impact of the US Court of Appeals for the Federal Circuit’s decision In re Kubin.
While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.
Patent term restoration has been adopted by several jurisdictions, with varying success. Mexico faces several issues with sanitary authorisations and patent examination, so patent term restoration would be a viable remedy for patent holders. The TPP might enable this.
The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system.
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.
While no court has tested it, Brazilian legislation seems to prohibit pay-for-delay settlements in the pharmaceutical industry. Gabriel Di Blasi argues that it’s time for a test case.
On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.
Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate.
For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.